NCT05979792View on ClinicalTrials.gov

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG

CAR-T Therapy

CAR-T cell infusion

Trial Locations (8)

230000

The First Affiliated Hospital of USTC, Hefei

361000

The First Affliliated Hospital of Xiamen University, Xiamen

450000

Henan Cancer Hospital, Zhengzhou

The First Affliated Hospital of Zhengzhou University, Zhengzhou

610000

West China Hospital Sichuan University, Chengdu

650000

The 920th Hospital of the Joint Service Support Force of the People's Liberation Army, Kunming

710000

The Affliliated Hospital of Northwest University, Xi’an

Unknown

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Zhao Weili

OTHER

NCT05979792 - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | Biotech Hunter | Biotech Hunter